Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future.

Concise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future.
复制标题

DOI:
10.1002/sctm.17-0196
复制
发表时间:
2018-04
影响因子:
6
通讯作者:
Cheng K
Cheng K
中科院分区:
医学2区
文献类型:
--
作者:
Tang JN;Cores J;Huang K;Cui XL;Luo L;Zhang JY;Li TS;Qian L;Cheng K

文献摘要

参考文献

相似文献

干细胞治疗是一种很有前途的组织再生策略。细胞治疗的疗效是通过直接和间接机制来实现的。然而,干细胞治疗在临床上的应用受到一些限制的阻碍。这篇简明的综述简要介绍了干细胞治疗缺血性心脏病。它总结了基于细胞和无细胞的范例,它们的局限性,以及使用它们来针对疾病的好处。干细胞转化医学2018;7:354-359
Stem cell therapy is a promising strategy for tissue regeneration. The therapeutic benefits of cell therapy are mediated by both direct and indirect mechanisms. However, the application of stem cell therapy in the clinic is hampered by several limitations. This concise review provides a brief introduction into stem cell therapies for ischemic heart disease. It summarizes cell‐based and cell‐free paradigms, their limitations, and the benefits of using them to target disease. stem cells translational medicine 2018;7:354–359
DOI: 10.1161/circulationaha.112.001075
发表时间: 2013-07-09
期刊: Circulation
影响因子: 37.8
作者:
Bolli R;Tang XL;Sanganalmath SK;Rimoldi O;Mosna F;Abdel-Latif A;Jneid H;Rota M;Leri A;Kajstura J
通讯作者: Kajstura J
DOI: 10.1007/s00395-013-0346-0
发表时间: 2013-05
影响因子: 9.5
作者:
Hong KU;Li QH;Guo Y;Patton NS;Moktar A;Bhatnagar A;Bolli R
通讯作者: Bolli R
DOI: 10.1161/circresaha.110.222703
发表时间: 2010-10-01
影响因子: 20.1
作者:
Hatzistergos KE;Quevedo H;Oskouei BN;Hu Q;Feigenbaum GS;Margitich IS;Mazhari R;Boyle AJ;Zambrano JP;Rodriguez JE;Dulce R;Pattany PM;Valdes D;Revilla C;Heldman AW;McNiece I;Hare JM
通讯作者: Hare JM
DOI: 10.1161/circresaha.116.310277
发表时间: 2017-04-14
影响因子: 20.1
作者:
Gao L;Kupfer ME;Jung JP;Yang L;Zhang P;Da Sie Y;Tran Q;Ajeti V;Freeman BT;Fast VG;Campagnola PJ;Ogle BM;Zhang J
通讯作者: Zhang J
DOI: 10.1161/circresaha.116.309935
发表时间: 2017-02-17
影响因子: 20.1
作者:
Agarwal U;George A;Bhutani S;Ghosh-Choudhary S;Maxwell JT;Brown ME;Mehta Y;Platt MO;Liang Y;Sahoo S;Davis ME
通讯作者: Davis ME